Abstract
Sanofi has licensed global rights to MannKind’s rapid-acting inhaled insulin Afrezza® (insulin human), which was approved by the US FDA in June 2014 for the treatment of diabetes mellitus at the third attempt. The drug will diversify Sanofi’s diabetes portfolio ahead of the 2015 patent expiry of its long-acting basal insulin analogue Lantus® (insulin glargine), which leads the diabetes market with sales of more than US$7 B in 2013. Considerable uncertainty surrounds the commercial potential of Afrezza, however.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
